AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) shares traded down 1.3% during mid-day trading on Tuesday . The company traded as low as $25.89 and last traded at $26.03, with a volume of 261,064 shares changing hands. The stock had previously closed at $26.37.

A number of research analysts recently issued reports on the stock. Raymond James Financial Inc. cut shares of AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 4th. Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 29th. Jefferies Group cut their price target on shares of AMAG Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating on the stock in a research note on Wednesday, August 10th. Deutsche Bank AG lowered their target price on shares of AMAG Pharmaceuticals from $42.00 to $35.00 and set a “hold” rating on the stock in a report on Monday, May 9th. Finally, JPMorgan Chase & Co. reiterated a “hold” rating and issued a $37.00 price objective on shares of AMAG Pharmaceuticals in a report on Thursday, May 5th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. AMAG Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $40.60.

The company’s market capitalization is $848.73 million. The company has a 50-day moving average price of $25.73 and a 200-day moving average price of $23.86.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping the Zacks’ consensus estimate of $1.20 by $0.25. During the same quarter in the previous year, the firm earned $1.12 earnings per share. The business had revenue of $127.40 million for the quarter, compared to the consensus estimate of $128.52 million. The company’s revenue for the quarter was up 46.7% on a year-over-year basis. Equities analysts forecast that AMAG Pharmaceuticals Inc. will post $5.47 EPS for the current fiscal year.

An institutional investor recently raised its position in AMAG Pharmaceuticals stock. Rhumbline Advisers boosted its stake in AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) by 10.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 37,447 shares of the specialty pharmaceutical company’s stock after buying an additional 3,420 shares during the period. Rhumbline Advisers owned 0.11% of AMAG Pharmaceuticals worth $1,131,000 at the end of the most recent quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.